Cargando…

Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)

BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-ne...

Descripción completa

Detalles Bibliográficos
Autores principales: Maeda, Haruka, Saito, Nobuo, Igarashi, Ataru, Ishida, Masayuki, Suami, Kazuya, Yagiuchi, Ai, Kimura, Yuya, Komino, Masaru, Arai, Hiromi, Morikawa, Toru, Motohashi, Iori, Miyazawa, Rei, Moriyama, Tetsu, Kamura, Hiroshi, Terada, Mayumi, Kuwamitsu, Osamu, Hayakawa, Tomoichiro, Sando, Eiichiro, Ohara, Yasuji, Teshigahara, Osamu, Suzuki, Motoi, Morimoto, Konosuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047210/
https://www.ncbi.nlm.nih.gov/pubmed/35438137
http://dx.doi.org/10.1093/cid/ciac292
_version_ 1784695679012044800
author Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Suami, Kazuya
Yagiuchi, Ai
Kimura, Yuya
Komino, Masaru
Arai, Hiromi
Morikawa, Toru
Motohashi, Iori
Miyazawa, Rei
Moriyama, Tetsu
Kamura, Hiroshi
Terada, Mayumi
Kuwamitsu, Osamu
Hayakawa, Tomoichiro
Sando, Eiichiro
Ohara, Yasuji
Teshigahara, Osamu
Suzuki, Motoi
Morimoto, Konosuke
author_facet Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Suami, Kazuya
Yagiuchi, Ai
Kimura, Yuya
Komino, Masaru
Arai, Hiromi
Morikawa, Toru
Motohashi, Iori
Miyazawa, Rei
Moriyama, Tetsu
Kamura, Hiroshi
Terada, Mayumi
Kuwamitsu, Osamu
Hayakawa, Tomoichiro
Sando, Eiichiro
Ohara, Yasuji
Teshigahara, Osamu
Suzuki, Motoi
Morimoto, Konosuke
author_sort Maeda, Haruka
collection PubMed
description BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16–64 years was also assessed. RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%–93.9%) among patients aged 16–64 years and 90.3% (95% CI, 73.6%–96.4%) among patients aged ≥65 years. Among patients aged 16–64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%–96.6%) within 1–3 months after full vaccination, and 86.4% (95% CI, 56.9%–95.7%) within 4–6 months. CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide.
format Online
Article
Text
id pubmed-9047210
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-90472102022-04-28 Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS) Maeda, Haruka Saito, Nobuo Igarashi, Ataru Ishida, Masayuki Suami, Kazuya Yagiuchi, Ai Kimura, Yuya Komino, Masaru Arai, Hiromi Morikawa, Toru Motohashi, Iori Miyazawa, Rei Moriyama, Tetsu Kamura, Hiroshi Terada, Mayumi Kuwamitsu, Osamu Hayakawa, Tomoichiro Sando, Eiichiro Ohara, Yasuji Teshigahara, Osamu Suzuki, Motoi Morimoto, Konosuke Clin Infect Dis Major Article BACKGROUND: Although high vaccine effectiveness of messenger RNA (mRNA) coronavirus disease 2019 (COVID-19) vaccines has been reported in studies in several countries, data are limited from Asian countries, especially against the Delta (B.1.617.2) variant. METHODS: We conducted a multicenter test-negative case-control study in patients aged ≥16 years visiting hospitals or clinics with signs or symptoms consistent with COVID-19 from 1 July to 30 September 2021, when the Delta variant was dominant (≥90% of SARS-CoV-2 infections) nationwide in Japan. Vaccine effectiveness of BNT162b2 or mRNA-1273 against symptomatic SARS-CoV-2 infections was evaluated. Waning immunity among patients aged 16–64 years was also assessed. RESULTS: We enrolled 1936 patients, including 396 test-positive cases and 1540 test-negative controls for SARS-CoV-2. The median age was 49 years, 53.4% were male, and 34.0% had underlying medical conditions. Full vaccination (receiving 2 doses ≥14 days before symptom onset) was received by 6.6% of cases and 38.8% of controls. Vaccine effectiveness of full vaccination against symptomatic SARS-CoV-2 infections was 88.7% (95% confidence interval [CI], 78.8%–93.9%) among patients aged 16–64 years and 90.3% (95% CI, 73.6%–96.4%) among patients aged ≥65 years. Among patients aged 16–64 years, vaccine effectiveness was 91.8% (95% CI, 80.3%–96.6%) within 1–3 months after full vaccination, and 86.4% (95% CI, 56.9%–95.7%) within 4–6 months. CONCLUSIONS: mRNA COVID-19 vaccines had high effectiveness against symptomatic SARS-CoV-2 infections in Japan during July–September 2021, when the Delta variant was dominant nationwide. Oxford University Press 2022-04-19 /pmc/articles/PMC9047210/ /pubmed/35438137 http://dx.doi.org/10.1093/cid/ciac292 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Major Article
Maeda, Haruka
Saito, Nobuo
Igarashi, Ataru
Ishida, Masayuki
Suami, Kazuya
Yagiuchi, Ai
Kimura, Yuya
Komino, Masaru
Arai, Hiromi
Morikawa, Toru
Motohashi, Iori
Miyazawa, Rei
Moriyama, Tetsu
Kamura, Hiroshi
Terada, Mayumi
Kuwamitsu, Osamu
Hayakawa, Tomoichiro
Sando, Eiichiro
Ohara, Yasuji
Teshigahara, Osamu
Suzuki, Motoi
Morimoto, Konosuke
Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title_full Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title_fullStr Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title_full_unstemmed Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title_short Effectiveness of Messenger RNA Coronavirus Disease 2019 Vaccines Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 Infections During the Delta Variant Epidemic in Japan: Vaccine Effectiveness Real-time Surveillance for SARS-CoV-2 (VERSUS)
title_sort effectiveness of messenger rna coronavirus disease 2019 vaccines against symptomatic severe acute respiratory syndrome coronavirus 2 infections during the delta variant epidemic in japan: vaccine effectiveness real-time surveillance for sars-cov-2 (versus)
topic Major Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9047210/
https://www.ncbi.nlm.nih.gov/pubmed/35438137
http://dx.doi.org/10.1093/cid/ciac292
work_keys_str_mv AT maedaharuka effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT saitonobuo effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT igarashiataru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT ishidamasayuki effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT suamikazuya effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT yagiuchiai effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT kimurayuya effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT kominomasaru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT araihiromi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT morikawatoru effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT motohashiiori effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT miyazawarei effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT moriyamatetsu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT kamurahiroshi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT teradamayumi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT kuwamitsuosamu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT hayakawatomoichiro effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT sandoeiichiro effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT oharayasuji effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT teshigaharaosamu effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT suzukimotoi effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus
AT morimotokonosuke effectivenessofmessengerrnacoronavirusdisease2019vaccinesagainstsymptomaticsevereacuterespiratorysyndromecoronavirus2infectionsduringthedeltavariantepidemicinjapanvaccineeffectivenessrealtimesurveillanceforsarscov2versus